FDA approves Novo Nordisk's subcutaneous Ozempic semaglutide for diabetes

FDA approved subcutaneous Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) as an adjunct to diet and exercise to improve glycemic control in adults

Read the full 240 word article

User Sign In